Cancer Antibody Drug Conjugates Market Report: Trends, Forecast and Competitive Analysis to 2030

Cancer Antibody Drug Conjugates Trends and Forecast

The future of the global cancer antibody drug conjugates market looks promising with opportunities in the blood cancer, breast cancer, ovary cancer, lung cancer, skin cancer, and brain tumor markets. The global cancer antibody drug conjugates market is expected to reach an estimated $20.9 billion by 2030 with a CAGR of 15.6% from 2024 to 2030. The major drivers for this market are growing incidence of cancer worldwide, continuous developments in conjugation technology and antibody engineering, and increased spending on research and development (R&D) initiatives.

A more than 150-page report is developed to help in your business decisions. Sample figures with some insights are shown below.

Cancer Antibody Drug Conjugates by Segment

The study includes a forecast for the global cancer antibody drug conjugates by product, application, technology, end use industry, and region.

Cancer Antibody Drug Conjugates Market by Product [Shipment Analysis by Value from 2018 to 2030]:

• Kadcyla
• Enhertu
• Adcetris
• Padcev
• Trodelvy
• Polivy
• Others

Cancer Antibody Drug Conjugates Market by Application [Shipment Analysis by Value from 2018 to 2030]:

• Blood Cancer
• Breast Cancer
• Ovary Cancer
• Lung Cancer
• Skin Cancer
• Brain Tumor
• Others

Cancer Antibody Drug Conjugates Market by Technology [Shipment Analysis by Value from 2018 to 2030]:

• Cleavable
• Non-Cleavable

Cancer Antibody Drug Conjugates Market by End Use Industry [Shipment Analysis by Value from 2018 to 2030]:

• Hospitals
• Specialty Clinics
• Others

Cancer Antibody Drug Conjugates Market by Region [Shipment Analysis by Value from 2018 to 2030]:

• North America
• Europe
• Asia Pacific
• The Rest of the World

List of Cancer Antibody Drug Conjugates Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies cancer antibody drug conjugates companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the cancer antibody drug conjugates companies profiled in this report include-

• Seagen
• Takeda Pharmaceutical Company
• AstraZeneca
• F. Hoffmann-La Roche
• Pfizer
• Gilead Sciences
• Daiichi Sankyo Company
• GlaxoSmithKline
• Astellas Pharma
• ADC Therapeutics

Cancer Antibody Drug Conjugates Market Insights

Lucintel forecasts that kadcyla is expected to witness the highest growth over the forecast period due to growth in the incidence of cancer and the usage of ADCs in cancer therapy.

Within this market, breast cancer will remain the largest segment due to increasing prevalence of breast cancer across the globe.

APAC is expected to witness the highest growth over the forecast period due to growing strategic efforts by major industry participants and advantageous regional government programs.

Features of the Global Cancer Antibody Drug Conjugates Market

Market Size Estimates: Cancer antibody drug conjugates market size estimation in terms of value ($B).

Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.

Segmentation Analysis: Cancer antibody drug conjugates market size by product, application, technology, end use industry, and region in terms of value ($B).

Regional Analysis: Cancer antibody drug conjugates market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different product, application, technology, end use industry, and regions for the cancer antibody drug conjugates market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the cancer antibody drug conjugates market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

FAQ

Q1. What is the cancer antibody drug conjugates market size?

Answer: The global cancer antibody drug conjugates market is expected to reach an estimated $20.9 billion by 2030.

Q2. What is the growth forecast for cancer antibody drug conjugates market?

Answer: The global cancer antibody drug conjugates market is expected to grow with a CAGR of 15.6% from 2024 to 2030.

Q3. What are the major drivers influencing the growth of the cancer antibody drug conjugates market?

Answer: The major drivers for this market are growing incidence of cancer worldwide, continuous developments in conjugation technology and antibody engineering and increased spending on research and development (R&D) initiatives.

Q4. What are the major segments for cancer antibody drug conjugates market?

Answer: The future of the cancer antibody drug conjugates market looks promising with opportunities in the blood cancer, breast cancer, ovary cancer, lung cancer, skin cancer, and brain tumor markets.

Q5. Who are the key cancer antibody drug conjugates market companies?

Answer: Some of the key cancer antibody drug conjugates companies are as follows:

• Seagen
• Takeda Pharmaceutical Company
• AstraZeneca
• F. Hoffmann-La Roche
• Pfizer
• Gilead Sciences
• Daiichi Sankyo Company
• GlaxoSmithKline
• Astellas Pharma
• ADC Therapeutics

Q6. Which cancer antibody drug conjugates market segment will be the largest in future?

Answer: Lucintel forecasts that kadcyla is expected to witness the highest growth over the forecast period due to growth in the incidence of cancer and the usage of ADCs in cancer therapy.

Q7. In cancer antibody drug conjugates market, which region is expected to be the largest in next 5 years?

Answer: APAC is expected to witness the highest growth over the forecast period due to growing strategic efforts by major industry participants and advantageous regional government programs.

Q.8 Do we receive customization in this report?

Answer: Yes, Lucintel provides 10% customization without any additional cost.

This report answers following 11 key questions:

• Q.1. What are some of the most promising, high-growth opportunities for the cancer antibody drug conjugates market by product (kadcyla, enhertu, adcetris, padcev, trodelvy, polivy, and others), application (blood cancer, breast cancer, ovary cancer, lung cancer, skin cancer, brain tumor, and others), technology (cleavable and non-cleavable), end use industry (hospitals, specialty clinics, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
• Q.2. Which segments will grow at a faster pace and why?
• Q.3. Which region will grow at a faster pace and why?
• Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
• Q.5. What are the business risks and competitive threats in this market?
• Q.6. What are the emerging trends in this market and the reasons behind them?
• Q.7. What are some of the changing demands of customers in the market?
• Q.8. What are the new developments in the market? Which companies are leading these developments?
• Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
• Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
• Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?